Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
Condition: CLL/SLL Intervention: Drug: Orelabrutinib Sponsor: Wang Xin Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials